



Mab 3F3 with controls





Figure 1 (A)

Anti-PA Mab 3F3 (plate 1)

120
100
80
40
80
40
80
Conc. of Mab



-PA/LF15ng/ml PA/LF5ng/ml






Figure 1(B)

Conc. of Mab (ng/ ml)

405

1215

 \subseteq


Anti-PA Mab 6C3 (plate 2)

100

8

9

20








Figure 1 (C)





FIGURE 2(A): Enhancement




■ %Protection w/o E's % Protection with 3F3 HP under different conditions Figure 2 (B): Protection **Treatment** 85.0 65.0 -35.0 -55.0 -75.0

■ % Enhancement w/o ■ % Enhancement with E's % Enhancement with H4-19E9 HP under different conditions Ŗ Figure 3 (A): Enhancement Treatment સ્કૃ ₹. ¥ 25.0 -75.0 45.0 -35.0 -55.0 5.0 -15.0 % Enhancement

■ %P rotection w/o E's % Protection with H4-19E9 HP under different conditions Figure 3 (B): Protection Treatment % Protection 55.0 -35.0 -55.0 -75.0 85.0 65.0 45.0

(

Figure 4 (A): Enhancement



■ % Protection with □ %Protection w/o E's +CR-1 ■ %Protection w/o % Protection with 3F3 HP under different conditions Figure 4 (B): Protection **Treatment** -25.0 15.0 135.0 75.0 35.0 115.0 95.0 55.0 % Protection

Figure 4 (C): Enhancement




Figure 4 (D): Protection

